5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 51 points (0.4%) at 14,033 as of Tuesday, Feb. 19, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,948 issues advancing vs. 943 declining with 147 unchanged.

The Health Care sector currently sits up 2.7% versus the S&P 500, which is up 0.5%. Top gainers within the sector include Sanofi ( SNY), up 3.1%, Gilead ( GILD), up 1.8%, Merck ( MRK), up 1.2%, Pfizer ( PFE), up 0.9% and Novo Nordisk A/S ( NVO), up 0.7%. On the negative front, top decliners within the sector include Medtronic ( MDT), down 2.3%, Regeneron Pharmaceuticals ( REGN), down 2.2%, Aetna ( AET), down 1.7% and Cigna ( CI), down 1.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. GlaxoSmithKline ( GSK) is one of the companies pushing the Health Care sector higher today. As of noon trading, GlaxoSmithKline is up $0.27 (0.6%) to $45.89 on average volume Thus far, 1.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $45.70-$45.98 after having opened the day at $45.76 as compared to the previous trading day's close of $45.62.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $115.2 billion and is part of the drugs industry. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.59 (1.6%) to $38.67 on light volume Thus far, 1.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $38.00-$38.77 after having opened the day at $38.18 as compared to the previous trading day's close of $38.08.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.8 billion and is part of the drugs industry. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 2.7% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Teva Pharmaceutical Industries Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Express Scripts ( ESRX) is up $0.86 (1.5%) to $56.43 on heavy volume Thus far, 9.9 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $55.49-$59.21 after having opened the day at $58.30 as compared to the previous trading day's close of $55.57.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services in North America. Express Scripts has a market cap of $45.4 billion and is part of the health services industry. The company has a P/E ratio of 32.1, above the S&P 500 P/E ratio of 17.7. Shares are up 2.9% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.29 (0.8%) to $36.87 on light volume Thus far, 2.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $36.58-$36.98 after having opened the day at $36.58 as compared to the previous trading day's close of $36.58.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $60.4 billion and is part of the drugs industry. The company has a P/E ratio of 31.5, above the S&P 500 P/E ratio of 17.7. Shares are up 12.2% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Bristol-Myers Squibb Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.67 (0.9%) to $76.83 on light volume Thus far, 3.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $75.96-$76.88 after having opened the day at $76.04 as compared to the previous trading day's close of $76.16.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $211.1 billion and is part of the drugs industry. The company has a P/E ratio of 14.9, below the S&P 500 P/E ratio of 17.7. Shares are up 8.6% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit